Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127560771 | 12756077 | 1 | I | 20160906 | 20160916 | 20160916 | EXP | ES-MYLANLABS-2016M1038181 | MYLAN | VALERA RUBIO M, LABRADOR ANDUJAR N, RUBIO SALVADOR AR, CHACON LOPEZ-MUNIZ JI, DIAZ PANIAGUA L. PHARMACOLOGICAL APPROACH FOR THE MANAGEMENT OF ADRENOCORTICAL CARCINOMA: A CASE REPORT. EUR-J-CLIN-PHAM 2016;18(3):199-201. | 0.00 | Y | 0.00000 | 20160916 | OT | ES | ES |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127560771 | 12756077 | 1 | PS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | 800 MG | U | U | 90943 | ||||||||
127560771 | 12756077 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 50 MG/M2 ON DAY 1 | U | 0 | |||||||||
127560771 | 12756077 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 100 MG/M2 ON DAY 1 | U | 0 | |||||||||
127560771 | 12756077 | 4 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | 50 MG/M2 ON DAY 1, EVERY 21 DAYS | U | 0 | |||||||||
127560771 | 12756077 | 5 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 100 MG/M2 ON DAYS 1, 2 ,3, EVERY 21 DAYS | U | U | 0 | ||||||||
127560771 | 12756077 | 6 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 800 MG/M2 | U | U | 0 | ||||||||
127560771 | 12756077 | 7 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | 2000 MG/M2 | U | U | 0 | ||||||||
127560771 | 12756077 | 8 | SS | LIPOSOMAL DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Other | 20 MG/M2 ON DAY 1, EVERY 21 DAYS | U | U | 0 | ||||||||
127560771 | 12756077 | 9 | SS | LIPOSOMAL DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Other | 50 MG/M2 ON DAY 1, EVERY 21 DAYS | U | U | 0 | ||||||||
127560771 | 12756077 | 10 | SS | FILGRASTIM | FILGRASTIM | 1 | Unknown | 300 MCG, 5 DAYS | U | U | 0 | ||||||||
127560771 | 12756077 | 11 | C | MESNA. | MESNA | 1 | Unknown | 2000 MG/M2 ON DAYS 1-3 | U | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127560771 | 12756077 | 1 | Adrenocortical carcinoma |
127560771 | 12756077 | 2 | Adrenocortical carcinoma |
127560771 | 12756077 | 4 | Adrenocortical carcinoma |
127560771 | 12756077 | 5 | Adrenocortical carcinoma |
127560771 | 12756077 | 6 | Adrenocortical carcinoma |
127560771 | 12756077 | 7 | Adrenocortical carcinoma |
127560771 | 12756077 | 8 | Adrenocortical carcinoma |
127560771 | 12756077 | 10 | Adrenocortical carcinoma |
127560771 | 12756077 | 11 | Adrenocortical carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127560771 | 12756077 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127560771 | 12756077 | Blood creatinine abnormal | |
127560771 | 12756077 | Cystitis haemorrhagic | |
127560771 | 12756077 | Gastroenteritis | |
127560771 | 12756077 | Hyperadrenocorticism | |
127560771 | 12756077 | Mucosal inflammation | |
127560771 | 12756077 | Pancytopenia | |
127560771 | 12756077 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127560771 | 12756077 | 1 | 201206 | 0 | ||
127560771 | 12756077 | 2 | 200909 | 0 | ||
127560771 | 12756077 | 4 | 200909 | 0 | ||
127560771 | 12756077 | 6 | 201206 | 0 | ||
127560771 | 12756077 | 7 | 201012 | 0 | ||
127560771 | 12756077 | 8 | 201012 | 0 | ||
127560771 | 12756077 | 9 | 201203 | 0 | ||
127560771 | 12756077 | 11 | 201012 | 0 |